Disease · MONDO_0044751
chronic diarrheal disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic diarrheal disease. Diseases, record MONDO_0044751. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044751
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- chronic diarrheal disease
- Open Targets ID
- MONDO_0044751
- Other names
- chronic diarrhea, chronic diarrhoea, diarrheal disease, chronic
- Highest stage of its drugs
- Approval, for 1 of its 12 drugs, from TTD
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EUPATILIN | CHEMBL312750 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ALDAFERMIN | CHEMBL4298055 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANTIMONY | CHEMBL4297652 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| COLESEVELAM | CHEMBL6068331 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OPIUM | CHEMBL2107914 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OPIUM, POWDERED | CHEMBL2107915 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| NITAZOXANIDE | CHEMBL1401 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBENDAZOLE | CHEMBL1483 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELOBIXIBAT | CHEMBL3039515 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POLYETHYLENE GLYCOL | CHEMBL1201478 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FGF1 | FGF1/KLB | 1 | FGF1/KLB activator | Phase 2 | https://conductscience.org/library/genes/2246 | Drugs and targets |
| FGFR4 | FGFR4-KLB | 1 | FGFR4-KLB activator | Phase 2 | https://conductscience.org/library/genes/2264 | Drugs and targets |
| KLB | FGF1/KLB | 1 | FGF1/KLB activator; FGFR4-KLB activator | Phase 2 | https://conductscience.org/library/genes/152831 | Drugs and targets |
| SLC10A2 | Ileal sodium/bile acid cotransporter | 1 | Ileal bile acid transporter inhibitor | Unknown | https://conductscience.org/library/genes/6555 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00680836 | Gulf War Digestive Health Study | Not applicable | 54 | 2014-08-29 | Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov |
| NCT05130047 | Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) | Phase 2 | 30 | 2023-10-12 | Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea | ALDAFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT00911612 | Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? | Phase 2 | 24 | 2012-03-15 | Irritable Bowel Syndrome, Diarrhea | COLESEVELAM | Its record names the disease | ClinicalTrials.gov |
| NCT06436833 | Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen | Not applicable | 360 | Bowel Preparation Solution, Colonoscopy | ELOBIXIBAT, POLYETHYLENE GLYCOL | Its record names the disease | ClinicalTrials.gov | |
| NCT01070277 | Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea | Not applicable | 100 | Chronic Diarrhea, Abdominal Pain, Bloating | ALBENDAZOLE, TINIDAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT05690321 | Opium Tincture Against Chronic Diarrhea - Patients | Phase 2 | 11 | Chronic Diarrhea | OPIUM, OPIUM, POWDERED | Its record names the disease | ClinicalTrials.gov | |
| NCT00055107 | Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children | Phase 1/2 | 6 | HIV Infections, Cryptosporidiosis | NITAZOXANIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active Group vs Placebo Group: serious adverse events | 0 of 27 | 0 of 27 | 54 | NCT00680836 | Trial comparisons |
| Aldafermin (NGM282) vs Placebo: deaths from any cause | 0 of 15 | 0 of 15 | 30 | NCT05130047 | Trial comparisons |
| Aldafermin (NGM282) vs Placebo: serious adverse events | 1 of 15 | 0 of 15 | 30 | NCT05130047 | Trial comparisons |
| Colesevelam vs Placebo: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT00911612 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044751
GET https://conductscience.org/api/diseases/v1/MONDO_0044751/drugs